Alumis (ALMS) risk factors, FY2024 10-K

Other

1. 01Risk Factors Related to the Merger
2. 02The Merger may not be completed on the terms or timeline currently contemplated, or at all. Our stockholders will be subject to a number of material risks if the Merger is not completed on the terms or timeline currently contemplated, or at all
3. 03Litigation relating to the Merger, if any, could result in an injunction preventing the completion of the Merger and/or substantial costs to us
4. 04The Merger Agreement contains provisions that could discourage a potential competing acquiror of us or could result in any competing proposal being at a lower price than it might otherwise be
5. 05The pendency of the Merger could adversely affect our business and operations of us and ACELYRIN
6. 06The Merger may be completed even if one of the parties is subject to material and adverse impacts that are excluded from the definition of material adverse effect in the Merger Agreement
7. 07Our current stockholders will have a reduced ownership interest and voting power in the combined company after the Merger
8. 08Directors and executive officers of us and ACELYRIN have interests in the Merger that may be different from, or in addition to, those of other our stockholders and ACELYRIN stockholders, which could have influenced their decisions to support or approve the Merger
9. 09Financial projections regarding us and ACELYRIN may not prove accurate
10. 10The combined company may fail to realize the anticipated benefits of the Merger
11. 11The failure to successfully integrate the businesses and operations of us and ACELYRIN in the expected time frame may adversely affect the combined company’s future results
12. 12The success of the Merger will depend in part on the retention of personnel critical to the business and operations of the combined company due to, for example, their technical skills or management expertise

Risks Related to Our Financial Position and Need for Capital

1. 13We are a clinical stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, and have incurred substantial losses since our inception and anticipate incurring substantial and increasing losses for the foreseeable future
2. 14Biopharmaceutical product development is a highly speculative undertaking. It entails substantial upfront capital expenditures and significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval or become commercially viable
3. 15We will require substantial additional financing to achieve our goals and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce, or terminate our product development or future commercialization efforts

Risks Related to Product Candidate Development and Commercialization

1. 16Our clinical trials may reveal SAEs and AEs and may result in a safety or tolerability profile that could delay or prevent regulatory approval or market acceptance of ESK-001, A-005 or any future product candidates
2. 17ESK-001 treatment by the investigator: one serious infection case (peritonsillar abscess), two malignancy cases (non-small cell lung cancer, renal cell carcinoma), and one arthritis case. We continue to evaluate the safety profile of ESK-001 in our ongoing Phase 2 OLE and Phase 3 trials
3. 18Preliminary, “top-line” and interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available or are subject to audit and verification procedures that could result in material changes in the final data
4. 19We have conducted, are currently conducting, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials
5. 20Even if we receive regulatory approval for our current or future product candidates in the United States, we may never receive regulatory approval to market outside of the United States
6. 21We face competition from entities that have made substantial investments into the rapid development of competitor treatments for immunological indications, including large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in our current indications

Risks Related to Our Business and Operations

1. 22The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed
2. 23If our product candidates, if approved, do not achieve broad market acceptance, the revenue that we generate from their sales will be limited
3. 24We may expend our limited resources to pursue a particular product candidate in specific indications and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
4. 25We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business
5. 26We are dependent on the services of our management team and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer
6. 27Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
7. 28Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
8. 29Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could adversely affect our business, financial condition, results of operations and prospects
9. 30Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities
10. 31We have engaged in and may in the future engage in strategic transactions in the future, which could impact our liquidity, increase our expenses and present significant distractions to our management
11. 32Our ability to use our net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited
12. 33Recent and future changes to tax laws could materially adversely affect our company
13. 34Additionally, remote work has become more common and has increased risks to our information technology systems and data, as more of our personnel utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations
14. 35issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate acquired entities into our information technology environment and security program
15. 36Our operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by a wildfire, earthquake or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
16. 37Our projections regarding the market opportunities for our product candidates may not be accurate, and the actual market for our products may be smaller than we estimate
17. 38Our cash and cash equivalents may be exposed to failure of our banking institutions
18. 39Public opinion and scrutiny of immunology treatments may impact public perception of our company and product candidates, or may adversely affect our ability to conduct our business and our business plans

Risks Related to Intellectual Property

1. 40We cannot ensure that patent rights relating to inventions described and claimed in our or any future licensors pending patent applications will issue or that patents based on our or any future licensors patent applications will not be challenged and rendered invalid and/or unenforceable
2. 41We may not be able to protect our intellectual property rights throughout the world
3. 42Intellectual property rights do not necessarily address all potential threats to our competitive advantage
4. 43We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates
5. 44We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
6. 45asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks
7. 46We may become involved in third-party claims of intellectual property infringement, which may prevent or delay our product discovery and development efforts
8. 47any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects
9. 48We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses
10. 49We may become subject to claims challenging the inventorship or ownership of our or any future licensors’ patents and other intellectual property
11. 50We may form or seek collaborations or strategic alliances or enter into licensing arrangements in the future, and we may neither enter into, nor realize the benefits of, such alliances or licensing arrangements
12. 51If we fail to comply with our obligations in agreements under which we in-license or acquire development or commercialization rights to product candidates, or data from third parties, we could lose such rights that are important to our business
13. 52Any license agreements we enter into in the future may be subject to certain rights retained by third parties
14. 53Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
15. 54Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated as a result of noncompliance with these requirements
16. 55Patent terms may be inadequate to protect our competitive position on products or product candidates for an adequate amount of time
17. 56If we do not obtain patent term extension for our product candidates, our business may be materially harmed
18. 57If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
19. 58We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
20. 59If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

Risks Related to Government Regulation

1. 60The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
2. 61Recently enacted legislation, future legislation and other healthcare reform measures may increase the difficulty and cost for us to obtain regulatory approval for and commercialize our product candidates and may affect the prices we may set
3. 62Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any
4. 63In addition to data privacy and security laws, we are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful

Risks Related to Our Reliance on Third Parties

1. 64We may have conflicts with any future licensors or collaborators that could delay or prevent the development or commercialization of our product candidates
2. 65the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected
3. 66candidates to participants in preclinical and clinical trials, or to provide product for treatment of participants once approved, would be jeopardized
4. 67The operations of our suppliers, most of which are located outside of the United States, are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations and prospects

Risks Related to Ownership of Our Common Stock

1. 68As a result of our history of losses and negative cash flows from operations, our consolidated financial statements contain a statement regarding a substantial doubt about our ability to continue as a going concern
2. 69An active and liquid trading market for our common stock may not develop, and you may not be able to resell your shares of common stock at or above the price you paid for them
3. 70Our stock price is likely to continue to be volatile, which could result in substantial losses for our investors
4. 71Sales of a substantial number of shares of our common stock could cause our stock price to fall
5. 72Our principal stockholders and management own a significant percentage of our common stock and will be able to control matters subject to stockholder approval
6. 73We are an “emerging growth company” and a “smaller reporting company” and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
7. 74Further, there is no guarantee that the exemptions available under the JOBS Act will result in significant savings. To the extent that we choose not to use exemptions from various reporting requirements under the JOBS Act, we will incur additional compliance costs, which may impact our financial condition
8. 75Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay an acquisition of us that may be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management
9. 76In addition, Section 203 of the Delaware General Corporation Law (“DGCL”) may discourage, delay or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock
10. 77is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act
11. 78Our board of directors is authorized to issue and designate shares of our preferred stock without stockholder approval
12. 79Because we do not anticipate paying any dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain
13. 80The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions
14. 81Unstable economic and market conditions may have serious adverse consequences on our business, financial condition and stock price
15. 82If securities or industry analysts do not publish research or reports about our business, or if they publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
16. 83We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices
17. 84Failure to establish and maintain effective internal control over financial reporting could adversely affect our business and if investors lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be negatively affected
18. 85Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
19. 86We may be subject to securities litigation, which is expensive and could divert management attention